ID: MRFR/Pharma/0248-HCR | February 2021 | Region: Global | 106 pages
Paresthesia is an abnormal sensation of the skin such as numbness, burning, pricking, and many other. On the basis of severity, they are acute or chronic. Some of the major causes of for the diseases are vitamin deficiency, hyperventilation syndrome, or by the use of anesthesia. The paresthesia treatment market is majorly driven by increasing prevalence of the paresthesia, changing lifestyle and poor diet. Furthermore, development in the healthcare expenditure, the government support for the research & development for new and better treatment have fuelled the paresthesia treatment market growth. However, lack of effectiveness and unavailability of precise treatment may hinder the paresthesia treatment market growth over the forecasted period.
Paresthesia Treatment market is expecting a healthy growth at a CAGR of 7.2 % during the forecast period 2017-2023.
The paresthesia treatment market is segmented on the basis of types, treatments, and end users. On the basis of types, the paresthesia treatment market is segmented into acute paresthesia, chronic paresthesia. On the basis of treatment, the paresthesia treatment market is segmented into immunosuppressant, anticonvulsants, topical creams, antivirals, and others. Immunosuppressant is further classified into prednisone, intravenous gamma globulin, and others. Topical creams are further classified into lidocaine, prilocaine, and other. On the basis of end users the paresthesia treatment market is segmented into hospitals, clinics, diagnosis centers, and others.
Source- World Health Organization (WHO, white paper, company presentation, annual reports
America dominates the paresthesia treatment market owing to the presence of a large number of patients with paresthesia and well developed technology. Furthermore, the government support for the research & development, and high healthcare expenditure have supported the growth of the paresthesia treatment market. Europe accounts for the second largest market, which is followed by Asia Pacific. Asia Pacific is the fastest growing paresthesia treatment market due to the presence of the huge opportunities in the market. India and China is the major contributor to the paresthesia treatment market owing to the presence of huge population base and rapidly growing economies. The Middle East & Africa holds the lowest share in the market.
Some of the major players in the paresthesia treatment market are Medtronic (UK), Omron Healthcare, Inc. (US), Boston Scientific Corporation (US), Stimwave LLC, (US), Nevro Corp. (US), Cyberonics, Inc. (US), EnteroMedics Inc. (US), St. Jude Medical, LLC. (US), Bio-Medical Research Ltd. (UK), Baxter (US), Stryker (US), GlaxoSmithKline plc.(UK).
|Market Size||2027: Significant Value|
|CAGR||7.2 % (2017-2023)|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Types, Treatments, and End Users|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Medtronic (UK), Omron Healthcare, Inc. (US), Boston Scientific Corporation (US), Stimwave LLC, (US), Nevro Corp. (US), Cyberonics, Inc. (US), EnteroMedics Inc. (US), St. Jude Medical, LLC. (US), Bio-Medical Research Ltd. (UK), Baxter (US), Stryker (US), GlaxoSmithKline plc.(UK).|
|Key Market Opportunities||New product launches and R&D Amongst major key Players|
|Key Market Drivers||